AI-enabled Target Safety Assessment

Systematic Safety Profiling of Lipoprotein(a)

Using Pheiron’s platform to assess the safety of Lp(a) lowering therapy, we find no indication of prominent safety signals in line with results from early Phase I and II trials. Our platform supports that therapeutic lowering of Lp(a) will be safe in humans.

Lack of safety is a major reason for late-stage clinical failure.

For many drug development programs, no animal models exist, and when they do, they often do not reflect human biology. Early trials are designed to get initial insight into the human safety and tolerability of drug candidates. However, they are too small to allow conclusions on the safety and efficacy in the broader population.

Pheiron uses advanced AI and human genetics to simulate large-scale randomized controlled trials and infer causal insights on human targets and populations. Using our platform, we help you anticipate on-target safety and adverse drug effects before any clinical trial.

Download our

Target Safety Assessment


Enter your details to learn more.

Find us on:

Something went wrong while submitting the form.